Literature DB >> 10395689

Studies with double cytokine-deficient mice reveal that highly polarized Th1- and Th2-type cytokine and antibody responses contribute equally to vaccine-induced immunity to Schistosoma mansoni.

K F Hoffmann1, S L James, A W Cheever, T A Wynn.   

Abstract

A fundamental obstacle to vaccine development in schistosomiasis mansoni is a lack of understanding of what type of an immune response should be invoked. We have addressed this central issue by using the radiation-attenuated cercariae vaccine in mice genetically engineered to exhibit highly polarized type 1 (IL-10/IL-4-deficient) or type 2 (IL-10/IL-12-deficient) cytokine and Ab phenotypes. Our data show that while significant differences in immunity exist after a single vaccination with irradiated cercariae in double cytokine-deficient vs wild-type mice, these differences disappear after two vaccinations. The most important finding of these studies, however, was revealed in vaccinated IL-10-deficient mice. These mice developed a mixed and elevated type 1- and type 2-associated immune response and developed anti-schistosome immunity at levels equal to or better than those in wild-type mice. This immunity in IL-10-deficient mice correlated with higher parasite-specific Ab titers, greater proliferative capacity of lymphocytes, increased frequency of IFN-gamma- and IL-4-secreting cells, elevated perivascular/peribronchial inflammatory responses in the lung, and greater in vitro schistosomulacidal capacity of parasite Ag-elicited cells. These results suggest that optimal vaccine-induced immunity against schistosomes is linked not to the development of a highly polarized response, but, rather, to the induction of both type 1- and type 2-associated immune responses.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10395689

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  52 in total

1.  Human immune responses to Schistosoma mansoni vaccine candidate antigens.

Authors:  A Ribeiro de Jesus; I Araújo; O Bacellar; A Magalhães; E Pearce; D Harn; M Strand; E M Carvalho
Journal:  Infect Immun       Date:  2000-05       Impact factor: 3.441

Review 2.  Immunology of parasitic helminth infections.

Authors:  Andrew S MacDonald; Maria Ilma Araujo; Edward J Pearce
Journal:  Infect Immun       Date:  2002-02       Impact factor: 3.441

3.  Matrix metalloproteinase 12-deficiency augments extracellular matrix degrading metalloproteinases and attenuates IL-13-dependent fibrosis.

Authors:  Satish K Madala; John T Pesce; Thirumalai R Ramalingam; Mark S Wilson; Samantha Minnicozzi; Allen W Cheever; Robert W Thompson; Margaret M Mentink-Kane; Thomas A Wynn
Journal:  J Immunol       Date:  2010-02-24       Impact factor: 5.422

Review 4.  Diversity and dialogue in immunity to helminths.

Authors:  Judith E Allen; Rick M Maizels
Journal:  Nat Rev Immunol       Date:  2011-06       Impact factor: 53.106

5.  Helicobacter hepaticus-induced colitis in interleukin-10-deficient mice: cytokine requirements for the induction and maintenance of intestinal inflammation.

Authors:  M C Kullberg; A G Rothfuchs; D Jankovic; P Caspar; T A Wynn; P L Gorelick; A W Cheever; A Sher
Journal:  Infect Immun       Date:  2001-07       Impact factor: 3.441

6.  The IL-21 receptor augments Th2 effector function and alternative macrophage activation.

Authors:  John Pesce; Mallika Kaviratne; Thirumalai R Ramalingam; Robert W Thompson; Joseph F Urban; Allen W Cheever; Deborah A Young; Mary Collins; Michael J Grusby; Thomas A Wynn
Journal:  J Clin Invest       Date:  2006-06-15       Impact factor: 14.808

7.  Nucleic acid vaccination with Schistosoma mansoni antioxidant enzyme cytosolic superoxide dismutase and the structural protein filamin confers protection against the adult worm stage.

Authors:  Rosemary M Cook; Claudia Carvalho-Queiroz; Gregory Wilding; Philip T LoVerde
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

8.  Chronic intestinal nematode infection exacerbates experimental Schistosoma mansoni infection.

Authors:  Quentin D Bickle; Julie Solum; Helena Helmby
Journal:  Infect Immun       Date:  2008-09-29       Impact factor: 3.441

9.  Development and validation of a quantitative, high-throughput, fluorescent-based bioassay to detect schistosoma viability.

Authors:  Emily Peak; Iain W Chalmers; Karl F Hoffmann
Journal:  PLoS Negl Trop Dis       Date:  2010-07-27

10.  In the absence of CD154, administration of interleukin-12 restores Th1 responses but not protective immunity to Schistosoma mansoni.

Authors:  James P Hewitson; Paul A Hamblin; Adrian P Mountford
Journal:  Infect Immun       Date:  2007-05-07       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.